Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
10.04. | Aprea Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
10.04. | Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024 | 129 | GlobeNewswire (Europe) | Pre-clinical findings underscore the potential of APR-1051, a next-generation WEE1 kinase inhibitor, to be a well-tolerated and effective treatment for Cyclin E-overexpressing cancers IND for APR-1051... ► Artikel lesen | |
03.04. | Aprea Therapeutics files to sell 4.39M shares of common stock for holders | 1 | Seeking Alpha | ||
28.03. | Aprea Therapeutics Inc reports results for the quarter ended in December - Earnings Summary | 1 | Reuters | ||
26.03. | Aprea Therapeutics: Q4 Earnings Insights | 1 | Benzinga.com | ||
26.03. | Aprea Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
26.03. | Aprea Therapeutics GAAP EPS of -$0.92 | 1 | Seeking Alpha | ||
26.03. | Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update | 193 | GlobeNewswire (Europe) | First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation and potentially generate human efficacy data in H2 2024 U.S. FDA cleared IND for APR-1051, a highly selective... ► Artikel lesen | |
26.03. | Aprea Therapeutics, Inc. - 10-K, Annual Report | 3 | SEC Filings | ||
15.03. | Aprea therapeutics director buys $50k in company shares | 1 | Investing.com | ||
15.03. | Aprea Therapeutics director buys $50k of company stock | 1 | Investing.com | ||
15.03. | Aprea Therapeutics CFO buys $7,362 in company stock | 1 | Investing.com | ||
14.03. | Karolinska Development AB (publ): Karolinska Development's portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million | 108 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN, March 14, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics has received FDA approval of the company's IND application... ► Artikel lesen | |
12.03. | Aprea Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
11.03. | Why Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday? | 1 | Benzinga.com | ||
11.03. | Aprea Therapeutics secures up to $34 million in financing | 1 | Investing.com | ||
11.03. | Aprea Therapeutics announces private placement financing of up to $34M | 1 | Seeking Alpha | ||
11.03. | Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers | 77 | GlobeNewswire (Europe) | Company plans to initiate Phase 1 ACESOT-1051 (A Multi-Center Evaluation of WEE1 Inhibitor in Patients with Advanced Solid Tumors, APR-1051) clinical trial evaluating, highly selective, oral WEE1... ► Artikel lesen | |
05.03. | Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024 | 1 | GlobeNewswire (USA) | ||
06.02. | Aprea Therapeutics files IND for new cancer drug APR-1051 | - | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 9,160 | -4,98 % | Allianz, Evotec, Nel ASA, Nordex, TUI - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
QIAGEN | 37,940 | -1,65 % | Biotech Report: Evotec und Qiagen behauptet, US-Sektor verliert | (shareribs.com) Frankfurt / New York 18.04.2024 - Biotech-Aktien zeigen sich im freundlichen Handel uneinheitlich. Evotec und Qiagen notieren etwas fester. An der Wall Street geben Gilead Sciences und... ► Artikel lesen | |
VIKING THERAPEUTICS | 64,12 | +5,50 % | Viking Therapeutics: So lief das erste Quartal | Viking Therapeutics hat im ersten Quartal 2024 finanzielle und operative Verbesserungen verzeichnet, die über den Markterwartungen liegen. Trotz der Herausforderungen in der Biopharmabranche blieb das... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 7,840 | 0,00 % | Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX | ||
MORPHOSYS | 67,75 | +0,07 % | ÜBERNAHME-FIEBER bei Biotech-Aktien! Evotec, Bayer, Vidac Pharma - wer folgt auf Morphosys? | Im Biotech-Sektor herrscht Übernahme-Fieber. Zuletzt hat Genmab den Kauf von ProfoundBio, das US-Biotech-Unternehmen entwickelt Medikamente gegen Eierstock- und Gebärmutterschleimhautkrebs, für 1,8... ► Artikel lesen | |
DAY ONE BIOPHARMACEUTICALS | 13,210 | 0,00 % | Day One Biopharmaceuticals, Inc.: Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor | First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation RAPNO LGG overall response rate... ► Artikel lesen | |
BIONTECH | 80,70 | -2,36 % | BioNTech Komplettabsturz! | Für BioNTech-Aktionäre kommt es heute knüppeldick. Denn der Kurs notiert rund drei Prozent in der Verlustzone. Damit verbilligt sich der Wert jetzt auf nur noch 80,00 EUR. Ist das nur ein kurzzeitiger... ► Artikel lesen | |
BEAM THERAPEUTICS | 21,600 | 0,00 % | Expert Ratings For Beam Therapeutics | ||
SPRINGWORKS THERAPEUTICS | 44,200 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | ||
ARCUTIS BIOTHERAPEUTICS | 8,590 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Appoints David Topper as Chief Financial Officer | WESTLAKE VILLAGE, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage company focused on developing meaningful innovations in immuno-dermatology... ► Artikel lesen | |
IMMUNOVANT | 27,750 | 0,00 % | Should You Hold Immunovant (IMVT)? | ||
CABALETTA BIO | 12,180 | -6,02 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
ARVINAS | 31,600 | 0,00 % | Arvinas Inc.: Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer | NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 23,830 | -5,02 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, April 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide... ► Artikel lesen | |
JANUX THERAPEUTICS | 47,100 | 0,00 % | Aktien New York: Dow erholt sich vor Start in die Berichtssaison | NEW YORK (dpa-AFX) - Die US-Aktienmärkte haben sich am Donnerstag im Handelsverlauf von ihrer anfänglichen Schwächephase erholt. Der Dow Jones Industrial notierte zuletzt 0,12 Prozent im Plus bei 38... ► Artikel lesen |